Error: Twitter did not respond. Please wait a few minutes and refresh this page.
- Clinical Trial Probability of Success? Just How Probable Is A Great Outcome.
- Clinical Trial Success: How Do You Define Success?
- CLINICAL DEVELOPMENT: CLINICAL TRIAL DATA MANAGEMENT, STATISTICAL PROGRAMMING AND ANALYSIS, AND QUALITY ASSURANCE
- CLINICAL DEVELOPMENT: THE CLINICAL TRIAL CASE REPORT FORM AND CLINICAL TRIAL MONITORING
- Ensuring Clinical Trial Data Quality
- Researchers question whether you should really finish your antibiotics July 27, 2017The standing argument that failing to complete a course of antibiotics could fuel the rise of antibiotic resistance has little evidence, a group of United Kingdom researchers argue in a new paper. In an analysis published in the medical journal the BMJ on Thursday, they say that completing a course of antibiotics may instead increase the risk of resistance. […]
- Antibiotic of last resort amplified to halt superbugs May 30, 2017Scientists in the United States have developed a vital tool in the battle against superbugs by re-engineering a decades-old antibiotic.
- This STD is becoming 'smarter' and harder to treat July 8, 2017Gonorrhea is becoming harder and in some cases impossible to treat with antibiotics, the World Health Organization said.
- CDC identifies first US cases of drug-resistant fungal infection November 4, 2016Thirteen individuals have become ill from a serious and sometimes fatal fungal infection previously unseen in the United States, the Centers for Disease Control and Prevention said Friday. The fungus, Candida auris, is known to occur in health care settings such as hospitals and nursing homes.
- The microscopic critter that can survive almost anything July 27, 2017Tardigrades, often called the "water bears" or "moss piglets," are starting to reveal more secrets about their ability to survive extreme conditions that humans can't, according to a new study in the journal PLOS.
- Researchers question whether you should really finish your antibiotics July 27, 2017
Monthly Archives: February 2011
Dr Michael Silverman of BioStrategics Consulting Ltd, reviews the type of clinical trial end points to use at different clinical development phases of a pharmaceutical product. In my last blog I talked about the general concept of clinical trial end … Continue reading
Dr Michael Silverman of BioStrategics Consulting Ltd., reviews the use of efficacy end points in clinical trials and the needs of the different audiences, including corporate sponsors, scientists and academics, regulatory authorities and the consumer. The choice of clinical trial … Continue reading
Dr Michael Silverman of BioStrategics Consulting Ltd discusses some of the dilemmas associated with Phase 1 clinical study design and implementation in the field of oncology and the impact on drug development. Many of you are knowledgeable about Phase 1 … Continue reading
Dr Michael Silverman of BioStrategics Consulting Ltd discusses some of the more common mistakes made in Phase 2 clinical study design and implementation. Every so often, I run into someone who sees Phase 2 clinical studies as an unnecessary stage … Continue reading